Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB-0,59
PKN60,9560,98-0,67
Msft-1,00
Nokia3,75053,7995-0,41
IBM0,38
Mercedes-Benz Group AG57,5357,550,77
PFE-0,27
18.09.2024 23:06:51
Indexy online
AD Index online
select
AD Index online
 

  • 18.09.2024 22:00:00
Heron Therapeutics (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
1,95 2,63 0,05 1 802 716
After-hours18.09.2024 22:30:00
Poslední obchod Nákup / Prodej Změna (%) Změna (USD)
1,95 - - 2,63 0,05
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 18.09.2024
Popis společnosti
Obecné informace
Název společnostiHeron Therapeutics Inc
TickerHRTX
Kmenové akcie:Ordinary Shares
RICHRTX.O
ISIN-
Prioritní akciePreference Shares
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky30.06.2024
Počet zaměstnanců k 31.12.2023 126
Akcie v oběhu k 01.08.2024 151 668 017
MěnaUSD
Kontaktní informace
Ulice4242 Campus Point Court, Suite 200
MěstoSAN DIEGO
PSČ92121
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon18 582 514 400

Business Summary: Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Heron Therapeutics Inc revenues increased 15% to $70.7M. Net loss decreased 83% to $12.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Sales and marketing - Balancing value decrease of 37% to $22.3M (expense), Labor & Related Expenses in R&D decrease of 71% to $3.9M (expense).
Odvětvová klasifikace
TRBC2012Biotechnology & Medical Research (NEC)
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 18.09.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the BoardAdam Morgan4503.04.202303.04.2023
Chief Executive Officer, DirectorCraig Collard5803.04.202303.04.2023
Chief Financial Officer, Principal Accounting OfficerIra Duarte5529.03.202416.06.2023
Executive Vice President, Chief Development OfficerWilliam Forbes6206.06.202306.06.2023
Vice PresidentLisa Peraza4629.03.202413.10.2020